.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Merck
Colorcon
Cantor Fitzgerald
US Department of Justice
Farmers Insurance
Moodys
Queensland Health
Federal Trade Commission
US Army

Generated: June 26, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,747,545

« Back to Dashboard

Details for Patent: 5,747,545

Title: Method of preventing NMDA receptor complex-mediated Neuronal damage
Abstract:Disclosed is a method for decreasing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitroso-compound that generates nitric-oxide or related redox species, in a concentration effective to effect neuroprotection. Also disclosed is a method for decreasing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitroso-compound that generates nitric oxide (or a related redox species such as NO.sup.- or NO.sup.+ equivalent), or a physiologically concentration effective to cause such neuroprotection.
Inventor(s): Lipton; Stuart A. (Newton, MA)
Assignee: The Children's Medical Center Corporation (Boston, MA)
Filing Date:Mar 22, 1995
Application Number:08/407,973
Claims:1. A method for a preliminary screen of candidate NMDA channel antagonists for safety and efficacy, said method comprising

a) determining the time period required for the candidate to induce blockade of NMDA-receptor-associate ion channels;

b) determining the time period required for loss of said blockade of ion channels when administration of the compound ceases; and

c) selecting a compound with time periods (a) and (b) that are shorter than the time periods characteristic of MK-801, thereby enhancing the prospect that the candidate will be a clinically tolerated selective NMDA antagonist.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Dow
Deloitte
Colorcon
Fuji
Cantor Fitzgerald
Accenture
Moodys
Boehringer Ingelheim
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot